Piper Sandler Reiterates Overweight Rating on IO Biotech (IOBT)

September 16, 2024 7:47 AM UTC Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $10.00 price target on IO Biotech (NASDAQ: IOBT).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login